Von Angerer E, Biberger C, Leichtl S
Institut für Pharmazie, Universität Regensburg, Germany.
Ann N Y Acad Sci. 1995 Jun 12;761:176-91. doi: 10.1111/j.1749-6632.1995.tb31378.x.
2-Phenylindoles and isosteric structures such as benzo[b]furans and benzo[b]thiophenes were used as estrogen receptor binding moiety for the syntheses of new nonsteroidal antiestrogens. The antiestrogenic potency was considerably enhanced following the introduction of polar functional groups into the side chain in position 1 (indole) or 3 (benzofuran, benzothiophene). The amino compounds could be characterized as mixed agonist/antagonists. Among the derivatives with an amide group compounds without any agonistic activity both in vitro and in vivo were identified. The amide function can be replaced by alkylthio or alkylsulfonyl groups without changing the endocrine profile very much. In this study, the estrogenic activity was determined in a new transcription assay with luciferase as the reporter. The results obtained in this assay were in very good agreement with those from the conventional mouse uterine weight test. Antitumor activity was determined in hormone-sensitive MCF-7 breast cancer cells. There was no difference in activity between partial and pure estrogen antagonists. However, the derivatives with sulfur containing side chains were much more active than the corresponding heterocycles with amino or carbamoyl functions. They reached IC50-values of about 1 nM. 2-Phenylindoles and 2-phenylbenzothiophenes were rather similar in their potencies whereas the benzofuran derivatives were less active probably due to their lower binding affinities for the ER.
2-苯基吲哚以及苯并[b]呋喃和苯并[b]噻吩等等电子结构被用作雌激素受体结合部分,用于合成新型非甾体抗雌激素药物。在1位(吲哚)或3位(苯并呋喃、苯并噻吩)的侧链中引入极性官能团后,抗雌激素活性显著增强。氨基化合物可被表征为混合激动剂/拮抗剂。在具有酰胺基的衍生物中,鉴定出了在体外和体内均无任何激动活性的化合物。酰胺官能团可被烷硫基或烷基磺酰基取代,而不会对内分泌特性产生太大影响。在本研究中,以荧光素酶作为报告基因,通过一种新的转录测定法测定雌激素活性。该测定法得到的结果与传统小鼠子宫重量试验的结果非常吻合。在激素敏感的MCF-7乳腺癌细胞中测定抗肿瘤活性。部分雌激素拮抗剂和纯雌激素拮抗剂之间的活性没有差异。然而,含硫侧链的衍生物比具有氨基或氨基甲酰基功能的相应杂环化合物活性高得多。它们的IC50值约为1 nM。2-苯基吲哚和2-苯基苯并噻吩的效力相当相似,而苯并呋喃衍生物的活性较低,可能是因为它们对雌激素受体的结合亲和力较低。